Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study.

Gorlin syndrome Sonic Hedgehog basal cell carcinoma basaloid follicular hamartoma naevoid basal cell carcinoma syndrome

Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
17 Sep 2024
Historique:
received: 16 01 2024
revised: 06 06 2024
accepted: 23 06 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: aheadofprint

Résumé

Naevoid basal cell carcinoma syndrome (NBCCS) is a rare genodermatosis caused by germline mutations in genes of the Sonic Hedgehog (SHH) pathway and is characterised by early onset of multiple basal cell carcinomas (BCCs). Although skin tumours with follicular differentiation, notably basaloid follicular hamartoma (BFH), have been reported in NBCCS, their relations with BCC are poorly defined. In this context, the aim of this study was to clarify morphological, immunohistochemical ​and molecular features of BFH arising in a context of NBCCS. A total of 140 skin tumours from NBCCS and 140 control BCC tumours were reviewed, blinded to clinical data and classified as BCC or BFH. The morphological characteristics of these two groups were then compared. Twenty cases were submitted for immunohistochemical and molecular analysis. Thirty-three tumours among the exploratory cohort were classified as BFH and were exclusively detected in NBCCS patients. Histopathological criteria that were significantly different from BCC were as follows: a small size (<1.5 mm), connection to a hair follicle, arborescent organoid architecture, lack of cytological atypia and infundibulocystic differentiation. Immunohistochemical analysis confirmed activation of the SHH pathway in these lesions. Targeted next-generation sequencing suggested that MYCN and GLI2/3 amplifications and TP53 mutations might be involved in progression of these follicular tumours to BCC. Our study confirms the high prevalence of BFH, representing up to 24% of skin tumours in NBCCS and potentially being BCC precursors.

Identifiants

pubmed: 39455322
pii: S0031-3025(24)00230-7
doi: 10.1016/j.pathol.2024.06.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Simon Barbieux (S)

Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France. Electronic address: simon_barbieux@orange.fr.

Fanélie Jouenne (F)

Department of Tumors Genomics and Pharmacology, Hôpital Saint-Louis, AP-HP, Paris, France.

Marie-Christine Machet (MC)

Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France.

Sylvie Fraitag (S)

Department of Pathology, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.

Nicolas Macagno (N)

Department of Pathology, Centre Hospitalier de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France; CARADERM Network, France.

Maxime Battistella (M)

CARADERM Network, France; Department of Pathology, Hôpital Saint-Louis, AP-HP, Paris, France.

Bernard Cribier (B)

CARADERM Network, France; Department of Dermatology, Hôpitaux Universitaires et Université de Strasbourg, Strasbourg, France.

Pierre Sohier (P)

CARADERM Network, France; Department of Pathology, Hôpital Cochin, AP-HP, Centre-Université Paris Cité, Paris, France.

Sara Laurent-Roussel (S)

CARADERM Network, France; Department of Pathology, Hôpital Cochin, AP-HP, Centre-Université Paris Cité, Paris, France; National Center of Dermatopathology - La Roquette, Paris, France.

Agnès Carlotti (A)

Department of Pathology, Hôpital Cochin, AP-HP, Centre-Université Paris Cité, Paris, France.

Fanny Beltzung (F)

Department of Pathology, Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France.

Marie-Laure Jullié (ML)

CARADERM Network, France; Department of Pathology, Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France.

Isabelle Moulonguet (I)

Department of Pathology, Hôpital Saint-Louis, AP-HP, Paris, France.

Nicole Basset-Seguin (N)

CARADERM Network, France; Department of Dermatology, Hôpital Saint-Louis, AP-HP, Paris, France.

Lydia Deschamps (L)

CARADERM Network, France; Department of Pathology, Hôpital Bichat, AP-HP, Paris, France.

Samia Mourah (S)

Department of Tumors Genomics and Pharmacology, Hôpital Saint-Louis, AP-HP, Paris, France.

Mahtab Samimi (M)

CARADERM Network, France; Department of Dermatology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; 'Biologie des infections à polyomavirus' Team, UMR INRA ISP 1282, Université de Tours, Tours, France.

Serge Guyétant (S)

Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; 'Biologie des infections à polyomavirus' Team, UMR INRA ISP 1282, Université de Tours, Tours, France.

Thibault Kervarrec (T)

Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; CARADERM Network, France; 'Biologie des infections à polyomavirus' Team, UMR INRA ISP 1282, Université de Tours, Tours, France.

Classifications MeSH